The number of units you draw for a tirzepatide dose depends entirely on the concentration of your vial. On a U-100 insulin syringe, 100 units equals 1 mL. A 10 mg dose from a 10 mg/mL vial is 1.00 mL, or 100 units. The same 10 mg dose from a 20 mg/mL vial is 0.50 mL, or 50 units — half the volume for the identical dose.
This is education, not a dosing instruction. Use only the concentration, volume and units your prescriber and dispensing pharmacy give you in writing for the specific vial in your hand. If the label and your instructions disagree, stop and call the pharmacy.
Never carry dosing instructions from an old vial to a new one. Compounded tirzepatide concentrations are not standardized between pharmacies, and a vial at double the concentration requires half the volume for the same milligram dose. Drawing the old number of units from a new vial is the most common serious dosing error in this category, and it doubles or halves your dose without any visible sign.
| Vial concentration | 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg |
|---|---|---|---|---|---|---|
| 2.5 mg/mL | 1.00 mL · 100 units | 2.00 mL · 200 units | 3.00 mL · 300 units | 4.00 mL · 400 units | 5.00 mL · 500 units | 6.00 mL · 600 units |
| 5 mg/mL | 0.50 mL · 50 units | 1.00 mL · 100 units | 1.50 mL · 150 units | 2.00 mL · 200 units | 2.50 mL · 250 units | 3.00 mL · 300 units |
| 10 mg/mL | 0.25 mL · 25 units | 0.50 mL · 50 units | 0.75 mL · 75 units | 1.00 mL · 100 units | 1.25 mL · 125 units | 1.50 mL · 150 units |
| 12.5 mg/mL | 0.20 mL · 20 units | 0.40 mL · 40 units | 0.60 mL · 60 units | 0.80 mL · 80 units | 1.00 mL · 100 units | 1.20 mL · 120 units |
| 20 mg/mL | 0.12 mL · 12 units | 0.25 mL · 25 units | 0.38 mL · 38 units | 0.50 mL · 50 units | 0.62 mL · 62 units | 0.75 mL · 75 units |
Why compounded vials differ at all
A manufactured pen meters the dose for you: you dial a number and the device delivers it. A compounded multi-dose vial does not. The pharmacy chooses a concentration, prints it on the label, and the responsibility for converting milligrams into volume transfers to you and your prescriber. That transfer is the single biggest practical difference between the brand and compounded routes, and it is rarely mentioned in the marketing for either.
The three checks before every first injection from a new vial
- Concentration. Read it off the label in milligrams per millilitre. If it is not printed, do not use the vial — call the pharmacy.
- Volume for your dose. Confirm in writing what volume corresponds to your prescribed milligram dose from this specific concentration.
- Beyond-use date. Note the date of first puncture and discard at the stated date rather than when the vial empties.
What a syringe is calibrated for
A U-100 insulin syringe is marked in insulin units, where 100 units equals 1 mL. It is not marked in milligrams of anything. The units marking is a volume measurement being borrowed, which works fine provided the concentration is known and stated. It fails silently when it is assumed.
When to stop and ask
If the volume you calculate seems large enough to be uncomfortable to inject, if the number of units differs from your last vial, if the label is missing a concentration, or if the solution is cloudy, discoloured or contains particles — stop, do not inject, and contact the dispensing pharmacy. None of those is a reason to guess.
Tirzepatide Units on an Insulin Syringe: the shortest useful summary
Tirzepatide is a once-weekly injection titrated from 2.5 mg to a 15 mg ceiling in 2.5 mg steps at intervals of at least four weeks, producing roughly 15 to 21% mean weight reduction across the studied maintenance arms at 72 weeks and about 20% against semaglutide's 14% in the only head-to-head trial. It works while it is taken; the withdrawal evidence shows substantial regain after stopping. Compounded preparations cost from $133 a month and are not FDA-approved; brand product is approved and costs considerably more.
Those five facts decide most questions people arrive with. Everything else on this page is detail underneath them — which is worth reading before you spend $2,388 on a first year, but not worth confusing with the outline.
Tirzepatide Units on an Insulin Syringe: where to go next
If you have not chosen a program, price your expected maintenance dose with the projector rather than reading advertisements. If you have, check what it charges at 10 mg against the price-by-dose table. If you are struggling with side effects, the side-effect reference covers each one with reported frequencies and the red flags that need a clinician. And if a program has refused to name its pharmacy, the verification walkthrough explains why that single answer outranks any price difference.
People also ask about tirzepatide units insulin syringe
What is tirzepatide units insulin syringe?
Tirzepatide units insulin syringe is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does tirzepatide units insulin syringe apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does tirzepatide units insulin syringe cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is tirzepatide units insulin syringe FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Sources
- US prescribing information for tirzepatide (Zepbound and Mounjaro), Eli Lilly and Company.
- SURMOUNT-1 — tirzepatide once weekly for the treatment of obesity, NCT04184622.
- SURMOUNT-5 — tirzepatide versus semaglutide in adults with obesity, NCT05822830.
- US Food and Drug Administration, human drug compounding — compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing.
- Program pricing as recorded in our open dataset, with a verification date on every record.